The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
is there a link to TSX please
In the interest of updating reports on MXCP/Íde, extract from MXCP results 3rd.December.
The path to recovery for IDE has been a long and difficult one and at times it felt like one step forwards, two steps back. Nonetheless the teams within the business, both executive and operational, have worked wonders and they now have a good platform from which to grow. The business was refinanced at the beginning of 2019 by the issue of £10.0 million secured loan notes. MXC now holds £8.0 million of these loan notes plus accrued interest, alongside 43.1 per cent. of the equity of IDE. The refinancing means that IDE now has secure, long term funding and no external third-party debt as the loan notes are held solely by shareholders. Whilst there remain challenges, in recent times IDE has moved into positive territory by beginning to win significant renewals and new contracts, testament to the will, enthusiasm and dedication to customer service from the operational team. There still exists a general level of customer churn in IDE which has impacted current year revenue and profitability, but this continues to be addressed and once this ceases, we anticipate the business will have turned the corner and should achieve market levels of profitability, which it is more than capable of delivering.
We remain confident that we will see a complete return of our capital from IDE.
I would not mind a business i ran making £3.1 million profit lol
Better get your hands in the till and get buying for a hostile takeover now you can... the only way it's coming back to you now Jimmy
Mark cannot hear you covid trader
What K N O B head saying he is blocked just a Covid trader
911 news coming
Big turn around story happening here
Closed the gap
Wait for the mainstream news reports on TV tonight
Usain it says news next week
A 24-bed quarantine clinic in Whitechapel, London, has been earmarked for the initial challenge trials. It is run by hVivo, a spinout from Queen Mary University of London that was bought this year by Open Orphan, a Dublin-based pharmaceutical research organisation. Imperial College London is the project’s academic leader.
https://www.ft.com/content/b782f666-6847-4487-986c-56d3f5e46c0b
https://twitter.com/MylesMcNulty/status/1308679301370347522?s=20
11 weeks since #N4P began investigating the use of Nuvec as an oral delivery system.
Last week’s interims: “we are in the process of conducting preliminary feasibility studies as to its viability”.
Positive results would be company changing.
Expecting news shortly.
High risk!
https://twitter.com/Physiomics/status/1308692846803910656?s=20
The early-stage trial, led by a team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, found that the drug combination was safe, successfully hit its targets, and was effective against a variety of advanced cancers – including those that had stopped responding to chemotherapy.
https://spongeshare.com/research/fusion-antibodies-research-note-part-2/
5 holding rns today already lol